Natera (NASDAQ:NTRA) was given a new $205.00 price target on by analysts at Wells Fargo & Company.
Natera (NASDAQ:NTRA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finance]
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer